Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6866097 | 0.84 | EPHX1 (0.52) | ACHERAB9AMAPTNPSR1EPHX1 | |
| SCHEMBL4451188 | 0.84 | RAB9A (0.61) | ACHERAB9AMAPTNPSR1EPHX1 | |
| SCHEMBL590532 | 0.83 | EPHX1 (0.59) | ACHERAB9AMAPTNPSR1EPHX1 | |
| SCHEMBL8196152 | 0.81 | EPHX1 (0.48) | ACHERAB9AMAPTEPHX1NPC1 | |
| SCHEMBL3395703 | 0.81 | RAB9A (0.49) | ACHERAB9AMAPTNPSR1EPHX1 | |
| SCHEMBL17198918 | 0.80 | RAB9A (0.43) | ACHERAB9AMAPTNPSR1EPHX1 | |
| SCHEMBL9197261 | 0.79 | EPHX1 (0.55) | ACHERAB9AMAPTNPSR1EPHX1 | |
| SCHEMBL1579477 | 0.79 | — | — | |
| Methane SCHEMBL4457769 | 0.79 | RAB9A (0.51) | ACHERAB9AMAPTNPSR1EPHX1 | |
| SCHEMBL6687894 | 0.78 | EPHX1 (0.60) | ACHERAB9AMAPTNPSR1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114163633-B | Antimicrobial polymers capable of supramolecular assembly | 国际商业机器公司 | 2024-05-24 | — | — | CN | disclosed |
| CN-114163633-A | Antimicrobial polymers capable of supramolecular assembly | 国际商业机器公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-111491980-B | Antimicrobial polymers capable of supramolecular assembly | 国际商业机器公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-111491980-A | Antimicrobial polymers capable of supramolecular assembly | 国际商业机器公司 | 2020-08-04 | — | — | CN | disclosed |
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-05-19 | — | — | US | disclosed |
| EP-2321274-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2011-05-18 | — | — | EP | disclosed |
| EP-2310012-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE DERIVATIVES | Janssen Pharmaceutica N.V. (BE) | 2011-04-20 | — | — | EP | disclosed |
| EP-2282995-A1 | DERIVATIVES OF QUINOLINES AND QUINOXALINES AS PROTEIN TYROSINE KINASE INHIBITORS | Novartis AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2010005783-A1 | PYRROLIDINYL AND PIPERIDINYL COMPOUNDS USEFUL AS NHE-1 INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-01-14 | — | — | WO | disclosed |
| WO-2010002774-A1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2010-01-07 | — | — | WO | disclosed |
| EP-1448187-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | Bristol-Myers Squibb Company (US) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003047512-A2 | COMPOUNDS DERIVED FROM AN AMINE NUCLEUS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003048127-A1 | AROMATIC HETEROCYCLIC NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| WO-2002014349-A2 | NON-COVALENT INHIBITORS OF UROKINASE AND BLOOD VESSEL FORMATION | CORVAS INTERNATIONAL, INC. (US) | 2002-02-21 | — | — | WO | disclosed |
| EP-1133488-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2001-09-19 | — | — | EP | disclosed |
| EP-1015438-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2000-11-08 | — | — | EP | disclosed |
| EP-1015438-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-07-05 | — | — | EP | disclosed |
| WO-2000031067-A1 | PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS | CELLTECH THERAPEUTICS LIMITED (GB) | 2000-06-02 | — | — | WO | disclosed |
| WO-1999011637-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-03-11 | — | — | WO | disclosed |
| US-5859295-A | Canavanine analogs and their use as chemotherapeutic agents | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 1999-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118262-A1 | Pyrrolidinyl and Piperidinyl Compounds Useful as NHE-1 Inhibitiors | NHERF1, SLC9A1, SLC9A5 | ACHE 4466/4885RAB9A 698/4885MAPT 4665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.